These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15767502)

  • 1. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
    Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
    Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease.
    Borghammer P; Kumakura Y; Cumming P
    Arch Neurol; 2005 Sep; 62(9):1480; author reply 1480-1. PubMed ID: 16157762
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
    Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E
    Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
    Lee CS; Schulzer M; de la Fuente-Fernández R; Mak E; Kuramoto L; Sossi V; Ruth TJ; Calne DB; Stoessl AJ
    Arch Neurol; 2004 Dec; 61(12):1920-5. PubMed ID: 15596613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging.
    Eckert T; Feigin A; Lewis DE; Dhawan V; Frucht S; Eidelberg D
    Mov Disord; 2007 Jan; 22(2):167-73. PubMed ID: 17133454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of dopaminergic presynaptic function by [F-18] DOPA PET].
    Kato T
    Rinsho Shinkeigaku; 2007 Nov; 47(11):829-31. PubMed ID: 18210809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
    Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
    Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
    Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
    J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.
    Kas A; Bottlaender M; Gallezot JD; Vidailhet M; Villafane G; Grégoire MC; Coulon C; Valette H; Dollé F; Ribeiro MJ; Hantraye P; Remy P
    J Cereb Blood Flow Metab; 2009 Sep; 29(9):1601-8. PubMed ID: 19491921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
    Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
    J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
    Cochen V; Ribeiro MJ; Nguyen JP; Gurruchaga JM; Villafane G; Loc'h C; Defer G; Samson Y; Peschanski M; Hantraye P; Cesaro P; Remy P
    Mov Disord; 2003 Aug; 18(8):928-32. PubMed ID: 12889084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
    Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
    Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
    Cordes M; Poewe W
    Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of dysprosody in Parkinson's disease over time--a longitudinal study.
    Skodda S; Rinsche H; Schlegel U
    Mov Disord; 2009 Apr; 24(5):716-22. PubMed ID: 19117364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
    Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
    Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.